ACCELERON PHARMA INC. Deferred Tax Assets, Valuation Allowance
ACCELERON PHARMA INC. had Deferred Tax Assets, Valuation Allowance of $282.21 million as of 2020-12-31, per its 10-K filed 2021-02-25.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2021-02-25
- 2020-12-31: Deferred Tax Assets, Valuation Allowance $282.21M.
- 2019-12-31: Deferred Tax Assets, Valuation Allowance $225.97M.
- 2018-12-31: Deferred Tax Assets, Valuation Allowance $182.96M.
- 2017-12-31: Deferred Tax Assets, Valuation Allowance $145.66M.
| Period end | Deferred Tax Assets, Valuation Allowance |
|---|---|
| 2020-12-31 | $282.21M 10-K · filed 2021-02-25 |
| 2019-12-31 | $225.97M 10-K · filed 2021-02-25 |
| 2018-12-31 | $182.96M 10-K · filed 2020-02-27 |
| 2017-12-31 | $145.66M 10-K · filed 2019-02-27 |
| 2016-12-31 | $136.54M 10-K · filed 2018-02-27 |
| 2015-12-31 | $109.80M 10-K · filed 2017-03-01 |
| 2014-12-31 | $89.80M 10-K · filed 2016-02-25 |
| 2013-12-31 | $66.08M 10-K · filed 2015-03-02 |
| 2012-12-31 | $68.18M 10-K · filed 2014-03-17 |